Across 5 CF donors (3 nasal and 2 bronchial cell lines carrying a range of CFTR mutations and using both FDA-approved CFTR modulators and those in preclinical development, we found that patient-derived cell lines accurately predicted CFTR rescue in the parent primary cells. Here, CFTR is linked to cystic fibrosis.